<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35341748</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2430</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>353</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental neurology</Title>
          <ISOAbbreviation>Exp Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Spinal motor neuron transplantation to enhance nerve reconstruction strategies: Towards a cell therapy.</ArticleTitle>
        <Pagination>
          <StartPage>114054</StartPage>
          <MedlinePgn>114054</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2022.114054</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4886(22)00079-6</ELocationID>
        <Abstract>
          <AbstractText>Nerve transfers have become a powerful intervention to restore function following devastating paralyzing injuries. A major limitation to peripheral nerve repair and reconstructive strategies is the progressive, fibrotic degeneration of the distal nerve and denervated muscle, eventually precluding recovery of these targets and thus defining a time window within which reinnervation must occur. One proven strategy in the clinic has been the sacrifice and transfer of an adjacent distal motor nerve to provide axons to occupy, and thus preserve (or "babysit"), the target muscle. However, available nearby nerves are limited in severe brachial plexus or spinal cord injury. An alternative and novel proposition is the transplantation of spinal motor neurons (SMNs) derived from human induced pluripotent stem cells (iPSCs) into the target nerve to extend their axons to occupy and preserve the targets. These cells could potentially be delivered through minimally invasive or percutaneous techniques. Several reports have demonstrated survival, functional innervation, and muscular preservation following transplantation of SMNs into rodent nerves. Advances in the generation, culture, and differentiation of human iPSCs now offer the possibility for an unlimited supply of clinical grade SMNs. This review will discuss the previous reports of peripheral SMN transplantation, outline key considerations, and propose next steps towards advancing this approach to clinic. Stem cells have garnered great enthusiasm for their potential to revolutionize medicine. However, this excitement has often led to premature clinical studies with ill-defined cell products and mechanisms of action, particularly in spinal cord injury. We believe the peripheral transplantation of a defined SMN population to address neuromuscular degeneration will be transformative in augmenting current reconstructive strategies. By thus removing the current barriers of time and distance, this strategy would dramatically enhance the potential for reconstruction and functional recovery in otherwise hopeless paralyzing injuries. Furthermore, this strategy may be used as a permanent axon replacement following destruction of lower motor neurons and would enable exogenous stimulation options, such as pacing of transplanted SMN axons in the phrenic nerve to avoid mechanical ventilation in high cervical cord injury or amyotrophic lateral sclerosis.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bazarek</LastName>
            <ForeName>Stanley</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnston</LastName>
            <ForeName>Benjamin R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sten</LastName>
            <ForeName>Margaret</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandeville</LastName>
            <ForeName>Ross</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eggan</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>BioMarin Pharmaceutical Inc., San Rafael, CA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wainger</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Neurology and Anesthesia, Critical Care &amp; Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: brian.wainger@mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Justin M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: jmbrown@mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Exp Neurol</MedlineTA>
        <NlmUniqueID>0370712</NlmUniqueID>
        <ISSNLinking>0014-4886</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013119" MajorTopicYN="Y">Spinal Cord Injuries</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cell transplantation</Keyword>
        <Keyword MajorTopicYN="Y">Nerve regeneration</Keyword>
        <Keyword MajorTopicYN="Y">Nerve transfers</Keyword>
        <Keyword MajorTopicYN="Y">Spinal cord injury</Keyword>
        <Keyword MajorTopicYN="Y">Spinal motor neurons</Keyword>
        <Keyword MajorTopicYN="Y">Stem cell therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35341748</ArticleId>
        <ArticleId IdType="doi">10.1016/j.expneurol.2022.114054</ArticleId>
        <ArticleId IdType="pii">S0014-4886(22)00079-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35341748</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2430</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>353</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental neurology</Title>
          <ISOAbbreviation>Exp Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Spinal motor neuron transplantation to enhance nerve reconstruction strategies: Towards a cell therapy.</ArticleTitle>
        <Pagination>
          <StartPage>114054</StartPage>
          <MedlinePgn>114054</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2022.114054</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4886(22)00079-6</ELocationID>
        <Abstract>
          <AbstractText>Nerve transfers have become a powerful intervention to restore function following devastating paralyzing injuries. A major limitation to peripheral nerve repair and reconstructive strategies is the progressive, fibrotic degeneration of the distal nerve and denervated muscle, eventually precluding recovery of these targets and thus defining a time window within which reinnervation must occur. One proven strategy in the clinic has been the sacrifice and transfer of an adjacent distal motor nerve to provide axons to occupy, and thus preserve (or "babysit"), the target muscle. However, available nearby nerves are limited in severe brachial plexus or spinal cord injury. An alternative and novel proposition is the transplantation of spinal motor neurons (SMNs) derived from human induced pluripotent stem cells (iPSCs) into the target nerve to extend their axons to occupy and preserve the targets. These cells could potentially be delivered through minimally invasive or percutaneous techniques. Several reports have demonstrated survival, functional innervation, and muscular preservation following transplantation of SMNs into rodent nerves. Advances in the generation, culture, and differentiation of human iPSCs now offer the possibility for an unlimited supply of clinical grade SMNs. This review will discuss the previous reports of peripheral SMN transplantation, outline key considerations, and propose next steps towards advancing this approach to clinic. Stem cells have garnered great enthusiasm for their potential to revolutionize medicine. However, this excitement has often led to premature clinical studies with ill-defined cell products and mechanisms of action, particularly in spinal cord injury. We believe the peripheral transplantation of a defined SMN population to address neuromuscular degeneration will be transformative in augmenting current reconstructive strategies. By thus removing the current barriers of time and distance, this strategy would dramatically enhance the potential for reconstruction and functional recovery in otherwise hopeless paralyzing injuries. Furthermore, this strategy may be used as a permanent axon replacement following destruction of lower motor neurons and would enable exogenous stimulation options, such as pacing of transplanted SMN axons in the phrenic nerve to avoid mechanical ventilation in high cervical cord injury or amyotrophic lateral sclerosis.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bazarek</LastName>
            <ForeName>Stanley</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnston</LastName>
            <ForeName>Benjamin R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sten</LastName>
            <ForeName>Margaret</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mandeville</LastName>
            <ForeName>Ross</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eggan</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>BioMarin Pharmaceutical Inc., San Rafael, CA, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wainger</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Neurology and Anesthesia, Critical Care &amp; Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: brian.wainger@mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Justin M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: jmbrown@mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Exp Neurol</MedlineTA>
        <NlmUniqueID>0370712</NlmUniqueID>
        <ISSNLinking>0014-4886</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013119" MajorTopicYN="Y">Spinal Cord Injuries</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cell transplantation</Keyword>
        <Keyword MajorTopicYN="Y">Nerve regeneration</Keyword>
        <Keyword MajorTopicYN="Y">Nerve transfers</Keyword>
        <Keyword MajorTopicYN="Y">Spinal cord injury</Keyword>
        <Keyword MajorTopicYN="Y">Spinal motor neurons</Keyword>
        <Keyword MajorTopicYN="Y">Stem cell therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35341748</ArticleId>
        <ArticleId IdType="doi">10.1016/j.expneurol.2022.114054</ArticleId>
        <ArticleId IdType="pii">S0014-4886(22)00079-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
